(XERS) Xeris Pharmaceuticals - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.038m USD | Total Return: 28.2% in 12m
Avg Turnover: 8.85M
Qual. Beats: 0
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
P/E ratio 85.9
Share dilution 16.5% YoY
Altman Z'' -4.58 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Xeris Biopharma Holdings, Inc. (XERS) is a Chicago-based, commercial-stage biopharmaceutical firm specializing in endocrine and neurological therapies. The company’s primary portfolio includes Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushing’s syndrome. Its late-stage pipeline is currently focused on XP-8121, a weekly subcutaneous treatment for hypothyroidism currently in Phase 3 clinical trials.
The company utilizes its proprietary XeriSol and XeriLend formulation platforms to develop liquid-stable, high-concentration injectables. This business model focuses on reformulating existing drugs to improve delivery and patient adherence, a common strategy in the specialty pharmaceutical sector to extend patent life and reduce developmental risk compared to new molecular entities.
For a deeper look into the companys valuation metrics and financial health, consider reviewing the data available on ValueRay.
- Recorlev market share expansion drives revenue growth in Cushing’s syndrome segment
- Gvoke prescription volume and retail pharmacy penetration impact quarterly earnings
- XP-8121 Phase 3 clinical trial results dictate long-term valuation prospects
- Operating expenses and path to sustained profitability influence investor sentiment
- Keveyis pricing stability and patient retention affect core cash flow generation
| Net Income: 12.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 20.74 > 1.0 |
| NWC/Revenue: 42.27% < 20% (prev 30.74%; Δ 11.53% < -1%) |
| CFO/TA 0.12 > 3% & CFO 48.5m > Net Income 12.0m |
| Net Debt (152.6m) to EBITDA (44.9m): 3.40 < 3 |
| Current Ratio: 2.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.6m) vs 12m ago 16.52% < -2% |
| Gross Margin: 81.59% > 18% (prev 0.81%; Δ 8.08k% > 0.5%) |
| Asset Turnover: 89.01% > 50% (prev 70.55%; Δ 18.46% > 0%) |
| Interest Coverage Ratio: 1.13 > 6 (EBITDA TTM 44.9m / Interest Expense TTM 28.7m) |
| A: 0.34 (Total Current Assets 251.7m - Total Current Liabilities 118.6m) / Total Assets 392.0m |
| B: -1.71 (Retained Earnings -669.1m / Total Assets 392.0m) |
| C: 0.09 (EBIT TTM 32.3m / Avg Total Assets 353.7m) |
| D: -1.77 (Book Value of Equity -669.1m / Total Liabilities 379.0m) |
| Altman-Z'' = -4.58 = D |
| DSRI: 0.86 (Receivables 56.3m/46.3m, Revenue 314.9m/222.6m) |
| GMI: 0.99 (GM 81.59% / 80.99%) |
| AQI: 0.73 (AQ_t 0.29 / AQ_t-1 0.39) |
| SGI: 1.41 (Revenue 314.9m / 222.6m) |
| TATA: -0.09 (NI 12.0m - CFO 48.5m) / TA 392.0m) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of May 25, 2026, the stock is trading at USD 6.38 with a total of 1,157,519 shares traded.
Over the past week, the price has changed by -0.80%,
over one month by +4.03%,
over three months by -5.93% and
over the past year by +28.16%.
Xeris Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XERS.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.3 | 77% |
P/E Forward = 75.188
P/S = 3.2954
P/B = 79.7463
Revenue TTM = 314.9m USD
EBIT TTM = 32.3m USD
EBITDA TTM = 44.9m USD
Long Term Debt = 220.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 6.27m USD (from shortTermDebt, last quarter)
Debt = 264.4m USD (corrected: LT Debt 220.3m + ST Debt 6.27m) + Leases 37.8m
Net Debt = 152.6m USD (calculated: Debt 264.4m - CCE 111.8m)
Enterprise Value = 1.19b USD (1.04b + Debt 264.4m - CCE 111.8m)
Interest Coverage Ratio = 1.13 (Ebit TTM 32.3m / Interest Expense TTM 28.7m)
EV/FCF = 25.20x (Enterprise Value 1.19b / FCF TTM 47.2m)
FCF Yield = 3.97% (FCF TTM 47.2m / Enterprise Value 1.19b)
FCF Margin = 15.00% (FCF TTM 47.2m / Revenue TTM 314.9m)
Net Margin = 3.81% (Net Income TTM 12.0m / Revenue TTM 314.9m)
Gross Margin = 81.59% ((Revenue TTM 314.9m - Cost of Revenue TTM 58.0m) / Revenue TTM)
Gross Margin QoQ = 84.02% (prev 77.77%)
Tobins Q-Ratio = 3.04 (Enterprise Value 1.19b / Total Assets 392.0m)
Interest Expense / Debt = 10.84% (Interest Expense 28.7m / Debt 264.4m)
Taxrate = 0.0% (0.0 / 554k)
NOPAT = 32.3m (EBIT 32.3m * (1 - 0.00%))
Current Ratio = 2.12 (Total Current Assets 251.7m / Total Current Liabilities 118.6m)
Debt / Equity = 20.32 (Debt 264.4m / totalStockholderEquity, last quarter 13.0m)
Debt / EBITDA = 3.40 (Net Debt 152.6m / EBITDA 44.9m)
Debt / FCF = 3.23 (Net Debt 152.6m / FCF TTM 47.2m)
Total Stockholder Equity = 1.63m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.39% (Net Income 12.0m / Total Assets 392.0m)
RoE = 1.79% (Net Income TTM 12.0m / Total Stockholder Equity 670.7m)
RoCE = 3.63% (EBIT 32.3m / Capital Employed (Equity 670.7m + L.T.Debt 220.3m))
RoIC = 11.55% (NOPAT 32.3m / Invested Capital 279.7m)
WACC = 10.49% (E(1.04b)/V(1.30b) * Re(10.40%) + D(264.4m)/V(1.30b) * Rd(10.84%) * (1-Tc(0.0)))
Discount Rate = 10.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 11.83%
[DCF] Terminal Value 68.32% ; FCFF base≈47.2m ; Y1≈47.4m ; Y5≈50.2m
[DCF] Fair Price = 2.43 (EV 572.9m - Net Debt 152.6m = Equity 420.2m / Shares 172.6m; r=10.49% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.15 | # QB: 0
Revenue Correlation: 99.38 | Revenue CAGR: 34.36% | SUE: 1.25 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=-14.66% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=0.14 | Chg30d=+0.14% | Revisions=+14% | GrowthEPS=+0.0% | GrowthRev=+32.2%
EPS next Year (2027-12-31): EPS=0.40 | Chg30d=+6.61% | Revisions=+0% | GrowthEPS=+177.2% | GrowthRev=+22.7%
[Analyst] Revisions Ratio: +20%